Recombinant Proteins CDMOs with Clean FDA Inspection History

← All Recombinant Proteins CDMOs Best Clean FDA History Commercial Scale
Region: USA Europe Asia
9
CDMOs tracked
9
Fully scored
6
With FDA records
10
FDA inspections
64
EMA/MHRA GMP certs

Recombinant protein CDMOs make therapeutic proteins, enzymes, and growth factors using microbial (E. coli, yeast) or mammalian (CHO) expression. Choice of host turns on post-translational modification needs, scale economics, and downstream-purification complexity.

Selecting a recombinant protein CDMO turns on host-system experience, validated bioreactor scale, downstream purification and analytics, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 4 NAI (no action), 6 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Germany (24), Denmark (18), United States (10), Lithuania (8), Netherlands (5).

Last updated 2026-08-22. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
 80.6 99.9 2 insp · 23 GMP Available 2 programs
2
Lonza
Basel, Switzerland
 78.2 95.1 2 insp · 8 GMP — 1 programs
3
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
 86.9 100.0 3 insp · 0 GMP Available 0 programs
4
KB
KBI Biopharma
Durham, NC · Boulder, CO
 83.5 100.0 1 insp · 1 GMP Limited 0 programs
5
RB
Richter BioLogics
Hamburg, Germany
 82.9 100.0 0 insp · 9 GMP — 0 programs
6
WK
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
 81.6 100.0 0 insp · 13 GMP — 0 programs
7
NW
Northway Biotech
Vilnius, LT; Waltham (MA), USA
 80.8 100.0 0 insp · 8 GMP Available 0 programs
8
RB
Rentschler Biopharma
Laupheim, Germany
 79.9 99.3 1 insp · 2 GMP — 0 programs
9
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
 72.8 95.1 1 insp · 0 GMP Limited 0 programs
How we score CDMOs →

What to evaluate in a Recombinant Proteins CDMO

Expression host & scale
Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target.
Purification & analytics
Downstream complexity (multiple chromatography steps, refolding for E. coli) drives cost and timeline. Ask about the orthogonal analytics package — purity, identity, potency.
Regulatory readiness
Clean FDA 483 history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & commercial readiness
For programs heading to BLA, evaluate validated commercial scale and any approved-product track record.

Recombinant Proteins CDMOs — Frequently Asked Questions

Who are the top Recombinant Proteins CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Recombinant Proteins CDMOs include AGC Biologics, Lonza, Pharmaron Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Recombinant Proteins CDMOs have FDA inspection records?
CDMO Signal tracks 6 Recombinant Proteins CDMOs with FDA inspection records and 64 EMA/MHRA GMP certificates across the group.
What should I look for in a recombinant protein CDMO?
Confirm expression-host experience for your target (microbial vs mammalian), validated bioreactor scale, a strong downstream-purification platform, qualified analytics, and a clean FDA and EMA/MHRA record.
How is a recombinant protein CDMO different from a mAb CDMO?
There's significant overlap — mAbs are recombinant proteins. But mAb CDMOs are typically optimized for CHO-based platform processes, while general recombinant protein CDMOs handle a wider range of hosts and non-mAb formats (enzymes, growth factors, complex non-glycoproteins).
Related modalities
Biologics / mAb CDMOs mRNA / LNP CDMOs Cell Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome ADC Gene Therapy Cell & Gene Therapy